Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) Non Operating Investment Income (2020 - 2023)

Historic Non Operating Investment Income for Avidity Biosciences (RNA) over the last 4 years, with Q2 2023 value amounting to -$1.1 million.

  • Avidity Biosciences' Non Operating Investment Income fell 1843.75% to -$1.1 million in Q2 2023 from the same period last year, while for Jun 2023 it was $320000.0, marking a year-over-year increase of 11071.67%. This contributed to the annual value of -$2.5 million for FY2022, which is 127967.03% down from last year.
  • Latest data reveals that Avidity Biosciences reported Non Operating Investment Income of -$1.1 million as of Q2 2023, which was down 1843.75% from $1.2 million recorded in Q1 2023.
  • In the past 5 years, Avidity Biosciences' Non Operating Investment Income ranged from a high of $1.2 million in Q1 2023 and a low of -$1.8 million during Q1 2022
  • Its 4-year average for Non Operating Investment Income is -$242363.6, with a median of -$5000.0 in 2020.
  • The largest annual percentage gain for Avidity Biosciences' Non Operating Investment Income in the last 5 years was 51129.03% (2022), contrasted with its biggest fall of 9205000.0% (2022).
  • Over the past 4 years, Avidity Biosciences' Non Operating Investment Income (Quarter) stood at -$5000.0 in 2020, then tumbled by 3620.0% to -$186000.0 in 2021, then soared by 511.29% to $765000.0 in 2022, then tumbled by 248.63% to -$1.1 million in 2023.
  • Its Non Operating Investment Income stands at -$1.1 million for Q2 2023, versus $1.2 million for Q1 2023 and $765000.0 for Q4 2022.